We are live on ! Find out more
APYX icon

Apyx Medical

41 hedge funds and large institutions have $26.6M invested in Apyx Medical in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 6

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

5% more funds holding

Funds holding: 3941 (+2)

6% less capital invested

Capital invested by funds: $28.2M → $26.6M (-$1.55M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
41
Holders Change
+2
Holders Change %
+5.13%
% of All Funds
0.93%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
11
Increased
14
Reduced
6
Closed
9
Calls
Puts
Net Calls
Net Calls Change

APYX Hedge Fund Activity: Q4 2017 in Review

41 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Apyx Medical (APYX) for Q4 2017, worth a combined $26.6M — down 5.5% from $28.2M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new APYX positions and 9 closed out — a net gain of 2 holders — while 14 added to existing stakes and 6 trimmed.

The largest buyer was Archon Capital Management, adding an estimated $6.66M. The largest seller was Great Point Partners, exiting entirely with an estimated $6.18M sold.

  • 41 institutional investors held Apyx Medical (APYX) as of Q4 2017, up from 39 in Q3 2017.
  • Funds reported $26.6M of Apyx Medical stock for Q4 2017, down 5.5% quarter-over-quarter.
  • 11 funds opened new Apyx Medical positions in Q4 2017 and 9 closed out, a net change of +2 holders.
  • The largest Apyx Medical buyer in Q4 2017 was Archon Capital Management, an estimated $6.66M added.
  • The largest Apyx Medical seller in Q4 2017 was Great Point Partners, an estimated $6.18M sold.

Based on aggregated 13F filings for Q4 2017.